{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:26:39Z","timestamp":1790810799747,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.drup.2026.101449","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:23:55Z","timestamp":1784204635000},"page":"101449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["ZDHHC16-induced GPX2 S-palmitoylation promotes lenvatinib resistance and inhibits lenvatinib-induced immunogenic cell death in hepatocellular carcinoma"],"prefix":"10.1016","volume":"89","author":[{"given":"Long","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101449_bib1","article-title":"Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association","volume":"57","author":"Allaire","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.drup.2026.101449_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101449_bib3","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/gutjnl-2023-330826","article-title":"High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT","volume":"73","author":"Bu","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.drup.2026.101449_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113721","article-title":"Immunogenic cell death as interplay between physical anticancer modalities and immunotherapy","volume":"384","author":"Engelen","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drup.2026.101449_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cac2.12414","article-title":"Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib","volume":"43","author":"Eun","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.drup.2026.101449_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.freeradbiomed.2022.05.003","article-title":"The glutathione peroxidase family: Discoveries and mechanism","volume":"187","author":"Floh\u00e9","year":"2022","journal-title":"Free. Radic. Biol. Med."},{"key":"10.1016\/j.drup.2026.101449_bib7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101449_bib8","article-title":"Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity","volume":"6","author":"Gui","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.drup.2026.101449_bib9","article-title":"NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma","author":"Huang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2026.101449_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-025-02397-5","article-title":"Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies","volume":"24","author":"Jia","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101449_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS. One"},{"key":"10.1016\/j.drup.2026.101449_bib12","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101449_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101449_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101449_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2026.101449_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/cas.70203","article-title":"N6-Methyladenosine-Modified circNEK11 Promotes Hepatocellular Carcinoma Progression via the miR-1236-3p\/GPX2 Axis","author":"Li","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101449_bib17","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/s41467-019-11269-8","article-title":"Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101449_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrm2084","article-title":"Palmitoylation: policing protein stability and traffic","volume":"8","author":"Linder","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.drup.2026.101449_bib19","article-title":"Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity","volume":"4","author":"Liu","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.drup.2026.101449_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101449_bib21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101449_bib22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12916-023-03066-4","article-title":"ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization","volume":"21","author":"Lu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.drup.2026.101449_bib23","article-title":"Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC","volume":"11","author":"Lu","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.drup.2026.101449_bib24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ccell.2022.08.016","article-title":"Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses","volume":"40","author":"Mandula","year":"2022","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101449_bib25","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/cas.15719","article-title":"Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2","volume":"114","author":"Mei","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101449_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101173","article-title":"Post-translational modifications in drug resistance","volume":"78","author":"Miao","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101449_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12943-024-02195-5","article-title":"ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis","volume":"23","author":"Mo","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101449_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101114","article-title":"Cancer plasticity in therapy resistance: Mechanisms and novel strategies","volume":"76","author":"Niu","year":"2024","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101449_bib29","article-title":"Protein palmitoylation: biological functions, disease, and therapeutic targets","volume":"6","author":"Qian","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.drup.2026.101449_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-024-01963-5","article-title":"The p-MYH9\/USP22\/HIF-1\u03b1 axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma","volume":"9","author":"Shan","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101449_bib31","article-title":"Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges","volume":"6","author":"Song","year":"2025","journal-title":"Innov. (Camb. )"},{"key":"10.1016\/j.drup.2026.101449_bib32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1007\/s12072-023-10544-7","article-title":"Targeting NAD(+) metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression","volume":"17","author":"Sun","year":"2023","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.drup.2026.101449_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111194","article-title":"S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K\/AKT pathway","volume":"40","author":"Sun","year":"2022","journal-title":"Cell. Rep."},{"key":"10.1016\/j.drup.2026.101449_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jare.2022.03.012","article-title":"GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma","volume":"44","author":"Tan","year":"2023","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.drup.2026.101449_bib35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12967-025-06468-5","article-title":"GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma","volume":"23","author":"Tan","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101449_bib36","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT\/\u03b2-Catenin and Hippo Signaling Pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2026.101449_bib37","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/0008-5472.CAN-24-3196","article-title":"CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101449_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10409238.2017.1409191","article-title":"Protein depalmitoylases","volume":"53","author":"Won","year":"2018","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.drup.2026.101449_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/imr.13251","article-title":"Amplifying \"eat me signal\" by immunogenic cell death for potentiating cancer immunotherapy","volume":"321","author":"Xi","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.drup.2026.101449_bib40","article-title":"CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma","volume":"6","author":"Xu","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.drup.2026.101449_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12935-021-01894-z","article-title":"Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma","volume":"21","author":"Xu","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.drup.2026.101449_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102351","article-title":"Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma","volume":"54","author":"Xu","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.drup.2026.101449_bib43","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000209","article-title":"Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma","volume":"7","author":"Yamada","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.drup.2026.101449_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2025.08.066","article-title":"Copper ionophore complex ES-Cu synergizes with quercetin to target FDX1, promote cuproptosis, and reverse lenvatinib resistance in hepatocellular carcinoma cells","author":"Yang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.drup.2026.101449_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101264","article-title":"The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation","volume":"82","author":"Yang","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101449_bib46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ijc.35496","article-title":"Immunogenic cell death: A promising mechanism involving different therapeutic strategies for liver cancer","volume":"157","author":"Yang","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2026.101449_bib47","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2026.101449_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2532217","article-title":"Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation","volume":"26","author":"Yuan","year":"2025","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.drup.2026.101449_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41420-023-01770-x","article-title":"Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.drup.2026.101449_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12943-024-02030-x","article-title":"CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p\/NUPR1\/FTH1 axis","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101449_bib51","doi-asserted-by":"crossref","first-page":"eadp7302","DOI":"10.1126\/sciimmunol.adp7302","article-title":"Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity","volume":"9","author":"Zhang","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.drup.2026.101449_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101224","article-title":"DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal \u03b2-oxidation in hepatocellular carcinoma","volume":"81","author":"Zhang","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101449_bib53","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02674-x","article-title":"Endoplasmic reticulum stress in antitumor immunity and immunotherapy resistance: mechanisms and therapeutic implications","volume":"25","author":"Zhao","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101449_bib54","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.apsb.2022.02.021","article-title":"Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer","volume":"12","author":"Zheng","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2026.101449_bib55","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.7150\/thno.78377","article-title":"The palmitoylation of AEG-1 dynamically modulates the progression of hepatocellular carcinoma","volume":"12","author":"Zhou","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101449_bib56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/JHC.S401639","article-title":"Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3\/4 Ligands in Hepatocellular Carcinoma","volume":"10","author":"Zhou","year":"2023","journal-title":"J. Hepatocell. Carcinoma"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:02:50Z","timestamp":1789786970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":56,"alternative-id":["S1368764626001007"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101449","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZDHHC16-induced GPX2 S-palmitoylation promotes lenvatinib resistance and inhibits lenvatinib-induced immunogenic cell death in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101449"}}